Xdemvy is not currently approved or marketed in France [1]. The drug, Lifitegrast, is approved in the United States under the brand name Xiidra for the treatment of dry eye disease [2].
What is Xiidra used for?
Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease [2]. It works by blocking the interaction of two proteins, LFA-1 and ICAM-1, which are thought to play a role in the inflammation associated with dry eye disease [2].
When did Xiidra get approved in the US?
Xiidra received U.S. Food and Drug Administration (FDA) approval in July 2016 [3].
Are there other treatments for dry eye disease?
Yes, there are various treatments for dry eye disease, including artificial tears, prescription eye drops like Xiidra and cyclosporine (Restasis, Cequa), and punctal plugs [4]. Lifestyle modifications and addressing underlying conditions can also be part of a treatment plan [4].
When does Xiidra's patent expire?
Information on the specific patent expiry dates for Xiidra is available through patent tracking resources [5]. For example, DrugPatentWatch.com tracks patents and exclusivity periods for pharmaceuticals [5].
Who manufactures Xiidra?
Xiidra is manufactured by Takeda Pharmaceuticals [2].
What are the side effects of Xiidra?
The most common side effect of Xiidra is eye irritation [2]. Other potential side effects include blurred vision, altered taste, and decreased"];